Thursday, April 17, 2014
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

New drug, study method show breast cancer promise

SAN ANTONIO — A novel way to speed the testing of cancer drugs and quickly separate winners from duds has yielded its first big result: an experimental medicine that shows promise against a hard-to-treat form of breast cancer.

The method involves studying drugs in small groups of people and using advanced statistical techniques to analyze the results as they come in, instead of waiting for all the data to arrive.

Whether the drug, veliparib, ever makes it to market remains to be seen, but it has shown enough potential to advance to final-phase testing aimed at Food and Drug Administration approval.

Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion. Companies can’t afford many studies like that, and patients can’t wait years for potentially life-saving new medicines, said Don Berry, a biostatistician at the University of Texas MD Anderson Cancer Center.

He helped design the novel analytical method discussed Friday at the San Antonio Breast Cancer Symposium, an international conference.

Researchers testing a drug usually don’t see results until they’re all in, to prevent biasing the study. But several years ago, an unusual partnership decided to try a new way. It involves the National Cancer Institute, the FDA, drug companies, dozens of cancer research centers and charitable foundations.

The study, called I-SPY 2, puts small groups of women on experimental drugs or combinations, then gives them surgery to see what effect the medicines had. The best result is a complete response, where no signs of cancer remain.

Each patient’s results are analyzed as they come in, and advanced statistical methods are used to calculate probabilities that the drug would help in various situations, depending on which women had a complete response.

“This allows us to learn and adapt from each patient as the study goes on,” and results on early participants guide treatment that later ones get, said Dr. Hope Rugo of the University of California, San Francisco. When enough evidence indicates a high probability of success, the drug “graduates” to final-phase testing.

On Friday, Rugo gave results on veliparib, the first of seven drugs being tested. It is made by AbbVie Inc., a North Chicago, Ill., company recently spun off from Abbott Laboratories. It is in a new class of experimental medicines called PARP inhibitors, which target an enzyme cancer relies on to grow.

The I-SPY 2 testing suggests that adding the chemotherapy drug carboplatin and veliparib to usual chemo before surgery improved outcomes for women with “triple negative” breast cancer – tumors that are not fueled by estrogen, progesterone or the gene that the medicine Herceptin targets.

Up to 20 percent of breast cancers are this type, and they are more common in young women, blacks and Hispanics, and women with certain breast cancer gene mutations.

Researchers were able to determine the drug’s potential after tests in only 71 women and just six months of treatment. They calculated that tests of only 300 women with triple negative tumors are needed to give a definitive answer, and that the drug has at least a 90 percent probability of success in such patients. If more types of cancer are included, the probability of success drops to 55 percent.

The results show that “we can get early reads on something that is worth pursuing” and bail quickly on treatments that don’t help, said Dr. Carlos Arteaga of the Vanderbilt-Ingram Comprehensive Cancer Center.

Veliparib has now graduated and is eligible for testing in a definitive study. It’s not known how long that would take, but it surely would be shorter than the several years that traditional testing requires.

FDA officials have said that in certain cases, complete responses can be considered a basis for conditional approval of a drug, as long as follow-up tests are done after the product is on the market to prove that it indeed is improving survival.

Last week, another company participating in the I-SPY 2 study, Puma Biotechnology Inc., said its experimental drug neratinib had also graduated and would enter a definitive study. Results of the early testing will be presented at a cancer conference next year.

The San Antonio meeting is sponsored by the American Association for Cancer Research, Baylor College of Medicine and the UT Health Science Center.

___

Online:

I-SPY2 trial: http://www.ispy2.org

Cancer meeting: http://www.sabcs.org

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

Supervisor candidates square off at forum

By Barry Eberling | From Page: A1, 5 Comments | Gallery

 
Carli takes oath, now Vacaville’s 14th police chief

By Susan Winlow | From Page: A1 | Gallery

 
Huge jump in Solano median home price

By Brad Stanhope | From Page: A1, 3 Comments | Gallery

Donate a car, help build a house

By Amy Maginnis-Honey | From Page: A3

 
Solano DA hosts workshop to fight human trafficking

By Ian Thompson | From Page: A3, 1 Comment | Gallery

Suisun water rates won’t rise this year

By Ian Thompson | From Page: A3

 
 
Fairfield town hall on crime delayed

By Ryan McCarthy | From Page: A4, 4 Comments

Railway museum offers wine-tasting rides

By Adrienne Harris | From Page: A4

 
 
Drugs topic of cardiac class

By Adrienne Harris | From Page: A4

Weather for April 17, 2014

By Daily Republic | From Page: B12

 
Fairfield police log: April 15, 2014

By Susan Hiland | From Page: A12

Suisun City police log: April 15, 2014

By Susan Hiland | From Page: A12

 
Fairfield police log: April 14, 2014

By Susan Hiland | From Page: A12

Suisun Police log: April 14, 2014

By Susan Hiland | From Page: A12

 
.

US / World

Armed robber was never told to report to prison

By The Associated Press | From Page: A1

 
Body of California man who jumped into river found

By The Associated Press | From Page: A4

Lost sea lion in California found mile from water

By The Associated Press | From Page: A4

 
Seabird from Atlantic spotted on Alcatraz

By The Associated Press | From Page: A5

Ex-Bell city leader gets 12 years in prison

By The Associated Press | From Page: A5, 1 Comment

 
California delays decision on protecting gray wolf

By The Associated Press | From Page: A5

Court rules for environmentalists in water fight

By The Associated Press | From Page: A5

 
Governor calls special session on rainy day fund

By The Associated Press | From Page: A5, 1 Comment

Denver police eye 911 response time after killing

By The Associated Press | From Page: A10, 1 Comment

 
Man charged with marathon hoax is held on bail

By The Associated Press | From Page: A10

Geneva talks on Ukraine face steep hurdles

By The Associated Press | From Page: A10

 
Pro-Russian insurgents seize armored vehicles

By The Associated Press | From Page: A10

Ferry sinks off South Korea; 6 dead, 290 missing

By The Associated Press | From Page: A10

 
NATO ups military presence amid Russian threat

By The Associated Press | From Page: A10, 1 Comment

.

Opinion

In support of Pam Bertani

By Letter to the Editor | From Page: A11, 6 Comments

 
Parenting demands responsibility

By Ruben Navarrette | From Page: A11, 1 Comment

 
Let’s stop Fairfield’s future thugs

By Kelvin Wade | From Page: A11, 6 Comments

Obamacare news you probably missed

By Martin Schram | From Page: A11, 2 Comments

 
Editorial Cartoons for April 17, 2014

By Kim Durbin | From Page: A11

.

Living

A lesson in household budgeting

By Chris Erskine | From Page: A2

 
Today in History for April 17, 2014

By The Associated Press | From Page: A2

Community Calendar: April 17, 2014

By Susan Hiland | From Page: A2

 
Horoscopes for April 17, 2014

By Holiday Mathis | From Page: A9

 
.

Entertainment

TVGrid

By Daily Republic Syndicated Content | From Page: B4

 
Daniel Radcliffe on why New York audiences rock

By The Associated Press | From Page: A7

Alicia Silverstone out with book ‘Kind Mama’

By The Associated Press | From Page: A7

 
Jenny McCarthy announces engagement on ‘The View’

By The Associated Press | From Page: A7

Ailing Malcolm Young taking break from AC/DC

By The Associated Press | From Page: A7

 
Disney Channel’s ‘Jessie’ breaks romantic ground

By The Associated Press | From Page: A7

.

Sports

Vacaville’s Peralta to wrestle at San Francisco State

By Daily Republic staff | From Page: B1

 
Angels beat A’s 5-4 on Iannetta’s HR in 12th

By The Associated Press | From Page: B1 | Gallery

MEL, SCAC tangle in hoops all-star games

By Paul Farmer | From Page: B1

 
Sharks take goalie questions into rematch vs Kings

By The Associated Press | From Page: B1

 
Crawford’s 41 points leads Warriors over Nuggets

By The Associated Press | From Page: B1 | Gallery

IndyCar driver Saavedra fined $10K

By The Associated Press | From Page: B2

 
Sandoval’s single lifts Giants past Dodgers, 2-1

By The Associated Press | From Page: B2 | Gallery

Officer: Sharper’s DNA found on 1 Arizona victim

By The Associated Press | From Page: B2

 
Jets sign former Titans RB Chris Johnson

By The Associated Press | From Page: B2

Spieth ready for more after Masters success

By The Associated Press | From Page: B2

 
Backup QB Matt Flynn returns to Packers

By The Associated Press | From Page: B2

Atlanta lands MLS expansion team for 2017

By The Associated Press | From Page: B2

 
Bucks owner Herb Kohl reaches deal to sell team

By The Associated Press | From Page: B2

Sidney Rice agrees to terms with Seahawks

By The Associated Press | From Page: B2

 
Goodwin helps Suns to 104-99 win over Kings in finale

By The Associated Press | From Page: B2 | Gallery

 
.

Business

Yellen: Fed stimulus still needed for job market

By The Associated Press | From Page: B4

 
Some exempted from minimum wage, increased or not

By The Associated Press | From Page: B4

Fed survey: Growth picks up across most of US

By The Associated Press | From Page: B5

 
Bank of America posts loss, hurt by legal charges

By The Associated Press | From Page: B5

IBM posts lower 1Q earnings amid hardware slump

By The Associated Press | From Page: B5

 
Google’s 1Q earnings disappoint as ad prices slip

By The Associated Press | From Page: B5

.

Obituaries

.

Comics

Sally Forth

By Daily Republic Syndicated Content | From Page: A8

 
Peanuts

By Daily Republic Syndicated Content | From Page: A8

Wizard of Id

By Daily Republic Syndicated Content | From Page: A8

 
Beetle Bailey

By Daily Republic Syndicated Content | From Page: A8

For Better or Worse

By Daily Republic Syndicated Content | From Page: A8

 
Zits

By Daily Republic Syndicated Content | From Page: A8

Blondie

By Daily Republic Syndicated Content | From Page: A8

 
Get Fuzzy

By Daily Republic Syndicated Content | From Page: A8

Baldo

By Daily Republic Syndicated Content | From Page: A8

 
Dilbert

By Daily Republic Syndicated Content | From Page: A8

Frank and Ernest

By Daily Republic Syndicated Content | From Page: A8

 
Garfield

By Daily Republic Syndicated Content | From Page: A8

Rose is Rose

By Daily Republic Syndicated Content | From Page: A8

 
B.C.

By Daily Republic Syndicated Content | From Page: A8

Baby Blues

By Daily Republic Syndicated Content | From Page: A8

 
Pickles

By Daily Republic Syndicated Content | From Page: A8

Crossword

By Daily Republic Syndicated Content | From Page: A9

 
Sudoku

By Daily Republic Syndicated Content | From Page: A9

Word Sleuth

By Daily Republic Syndicated Content | From Page: A9

 
Cryptoquote

By Daily Republic Syndicated Content | From Page: A9

Bridge

By Daily Republic Syndicated Content | From Page: A9